2769-72-4

Basic information

• Product Name: T-BUTYL ISOCYANOACETATE
• Synonyms: 2-ISOCYANO ACETIC ACID TERT-BUTYL ESTER;T-BUTYL ISOCYANOACETATE;TERT-BUTYL ISOCYANOACETATE;2-Isocyanoacetic acid 1,1-dimethylethyl ester;tert-Butyl 2-isocyanoacetate;tert-Butyl isocyanoacetate technical, >=95% (GC)
• CAS NO: 2769-72-4
• Molecular Formula: C₇H₁₁NO₂
• Molecular Weight: 141.17
• Product Categories: Naphthyridine,Quinoline;Isocyanides;Nitrogen Compounds;Organic Building Blocks
• Mol File: 2769-72-4.mol
• Article Data: 8

Chemical Properties

• Boiling Point: 50 °C0.1 mm Hg(lit.)
• Flash Point: 82 °C
• Appearance: /
• Density: 0.97 g/mL at 20 °C(lit.)
• Refractive Index: n20/D 1.422
• Storage Temp.: −20°C
• BRN: 4130722
• CAS DataBase Reference: T-BUTYL ISOCYANOACETATE(CAS DataBase Reference)
• NIST Chemistry Reference: T-BUTYL ISOCYANOACETATE(2769-72-4)
• EPA Substance Registry System: T-BUTYL ISOCYANOACETATE(2769-72-4)

Safety Data

• Hazard Codes: Xn,Xi
• Statements: 20/22
• Safety Statements: 23-24/25
• RIDADR: UN 2810 6.1/PG 3
• WGK Germany: 3
• F: 8-9
• HazardClass: 6.1(b)
• PackingGroup: III
• Hazardous Substances Data: 2769-72-4(Hazardous Substances Data)

Usage

General Description

T-BUTYL ISOCYANOACETATE is a chemical compound with the molecular formula C7H11NO2. It is a clear, colorless liquid with a faint odor and is commonly used as an intermediate in organic synthesis. T-BUTYL ISOCYANOACETATE is known for its reactivity and is often used in the production of pharmaceuticals and agrochemicals. T-BUTYL ISOCYANOACETATE is also used in the creation of dyes and pigments, and in the synthesis of various organic compounds. It is important to handle this chemical with care and to follow proper safety protocols when working with it.

InChI:InChI=1/C7H11NO2/c1-7(2,3)10-6(9)5-8-4/h5H2,1-3H3

Upstream product

• 58948-98-4 potassium 2-isocyanoacetate 
• 5292-43-3 bromoacetic acid tert-butyl ester 
• 6456-74-2 Glycine tert-butyl ester 
• 107-59-5 tert-Butyl chloroacetate 
• 51354-15-5 tert-butyl 2-formamidoacetate 

Downstream Products

• 100780-39-0 t-Butyl 3-(p-methoxy-phenyl)-4-methylpyrrole-2-carboxylate 
• 2273-04-3 1-(2-nitrophenyl)urea 
• 88-74-4 2-nitro-aniline 
• 222026-11-1 4-ethyl-3-(4-nitro-phenyl)-1H-pyrrole-2-carboxylic acid tert-butyl ester 
• 1020852-28-1 tert-butyl (2-(2-chloroacetoxy)-3-phenylpropionylamino)acetate 
• 909870-40-2 2,5-anhydro-3,4,6-tri-O-benzyl-N-[(tert-butyloxycarbonyl)methyl]-2-deoxy-2-formamido-D-galacto-hexonamide 
• 1047991-01-4 2,5-anhydro-3,4,6-tri-O-benzyl-N-[(tert-butyloxycarbonyl)methyl]-2-deoxy-2-formamido-D-talo-hexonamide 
• 1047991-03-6 2,5-anhydro-3,4,6-tri-O-benzyl-N-[(tert-butyloxycarbonyl)methyl]-2-deoxy-2-(pent-4-enoylamido)-D-talo-hexonamide 
• 909870-42-4 2,5-anhydro-3,4,6-tri-O-benzyl-N-[(tert-butyloxycarbonyl)methyl]-2-deoxy-2-(pent-4-enoylamido)-D-galacto-hexonamide 
• 1047991-04-7 2,5-anhydro-3,4,6-tri-O-benzyl-N-[(tert-butyloxycarbonyl)methyl]-2-deoxy-2-{N-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-aminoacetamido}-D-talo-hexonamide 
• 909870-43-5 2,5-anhydro-3,4,6-tri-O-benzyl-N-[(tert-butyloxycarbonyl)methyl]-2-deoxy-2-{N-[(9H-fluoren-9-ylmethoxy)carbonyl]-2-aminoacetamido}-D-galacto-hexonamide 
• 1047991-02-5 2,5-anhydro-3,4,6-tri-O-benzyl-N-[(tert-butyloxycarbonyl)methyl]-2-deoxy-2-(p-nitrobenzamido)-D-talo-hexonamide 
• 909870-41-3 2,5-anhydro-3,4,6-tri-O-benzyl-N-[(tert-butyloxycarbonyl)methyl]-2-deoxy-2-(p-nitrobenzamido)-D-galacto-hexonamide 

Relevant articles and documents

-

-

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with CNS disorders. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating cognitive impairment associated with CNS disorders in a subject in need or at risk thereof, including age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI, Age-Associated Memory Impairment, Age Related Cognitive Decline, dementia, Alzheimer's Disease(AD), prodromal AD, PTSD, schizophrenia, bipolar disorder, ALS, cancer-therapy-related cognitive impairment, mental retardation, Parkinson's disease, autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction. It also relates to the use of an α5-containing GABAA receptor agonist (e.g., an α5-containing GABAA receptor positive allosteric modulator) in treating brain cancers (including brain tumors, e.g., medulloblastomas), and cognitive impairment associated therewith.

BENZODIAZEPINE DERIVATIVES, COMPOSITIONS, AND METHODS FOR TREATING COGNITIVE IMPAIRMENT

This invention relates to benzodiazepine derivatives, compositions comprising therapeutically effective amounts of those benzodiazepine derivatives and methods of using those derivatives or compositions in treating cognitive impairment associated with central nervous system (CNS) disorders. In particular, it relates to the use of a α5- containing GABAA receptor agonist (e.g., a α5-containing GABAA receptor positive allosteric modulator) as described herein in treating cognitive impairment associated with central nervous system (CNS) disorders in a subject in need or at risk thereof, including, without limitation, subjects having or at risk for age-related cognitive impairment, Mild Cognitive Impairment (MCI), amnestic MCI (aMCI), Age- Associated Memory Impairment (AAMI), Age Related Cognitive Decline (ARCD), dementia, Alzheimer' s Disease(AD), prodromal AD, post traumatic stress disorder (PTSD), schizophrenia, bipolar disorder, amyotrophic lateral sclerosis (ALS), cancer-therapy-related cognitive impairment, mental retardation, Parkinson' s disease (PD), autism spectrum disorders, fragile X disorder, Rett syndrome, compulsive behavior, and substance addiction.